AlphaHunt
Healthcare

INCY Stock Analysis

Incyte Corporation · current price $97.24 (-1.77% today)

★★★★ Quality 64/ Alpha Score
Solid setup — 21% revenue growth, 3/4 EPS beats, 27% net margin. Momentum, fundamentals and macro indicators are aligned.
LAST EARNINGS Incyte Corporation (INCY)

Latest earnings

EPS
$1.57 vs $1.47 est · +0.1% vs estimate BEAT
Revenue
$1.27B · +4.7% YoY
Stock reaction (1M)
+3.5%
Beat streak
3 of last 4 quarters

Key metrics

Alpha Score
64/100
Grade
B
Rev Growth YoY
+20.9%
30-day Momentum
+3.5%
Forward P/E
13.9×
Analyst Target
$109.09
Implied Upside
+10.7%

Latest news on INCY

Similar stocks in Healthcare

BIIB WST LLY WAT MRNA DGX

View all Healthcare stocks →

INCY — frequently asked

What is INCY's Alpha Score?

Incyte Corporation (INCY) currently has a TickerMover Alpha Score of 64/100, rated ★★★★ Quality. The Alpha Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Incyte Corporation (INCY) a buy?

TickerMover does not give buy or sell recommendations. INCY scores 64/100 (★★★★ Quality) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is INCY's score updated?

INCY's Alpha Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF, peer comparison and more — free during beta.

Open dashboard for INCY →
TickerMover is a research tool, not financial advice. Alpha Score is a composite signal — always do your own research before investing.
Last updated automatically every 5 minutes during US market hours.
Questions? support@tickermover.com